@article {Chodick2021.01.27.21250612, author = {Gabriel Chodick and Lilac Tene and Tal Patalon and Sivan Gazit and Amir Ben Tov and Dani Cohen and Khitam Muhsen}, title = {The effectiveness of the first dose of BNT162b2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization: real-world evidence}, elocation-id = {2021.01.27.21250612}, year = {2021}, doi = {10.1101/2021.01.27.21250612}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background BNT162b2 vaccines showed high efficacy against COVID-19 in a randomised controlled phase-III trial. A vaccine effectiveness evaluation in real life settings is urgently needed, especially given the global disease surge. Hence, we assessed the short-term effectiveness of the first dose of BNT162b2-vaccine against SARS-CoV-2 infection. Given the BNT162b2 Phase-III results, we hypothesized that the cumulative incidence of SARS-CoV-2 infection among vaccinees will decline after 12 days following immunization compared to the incidence during the preceding days.Methods We conducted a retrospective cohort study using data from 2{\textperiodcentered}6 million-member state-mandated health provider in Israel. Study population consisted of all members aged 16 or above years who were vaccinated with BNT162b2-vaccine between December/19/2020 and January/15/2021. We collected information regarding medical history and positive SARS-CoV-2 polymerase chain reaction test from days after first dose to January/17/2021. Daily and cumulative infection rates in days 13-24 were compared to days 1-12 after first dose using Kaplan-Meier survival analysis and generalized linear models.Findings Data of 503,875 individuals (mean age 59{\textperiodcentered}7 years SD=14{\textperiodcentered}7, 47{\textperiodcentered}8\% males) were analysed, of whom 351,897 had 13-24 days of follow-up. The cumulative incidence of SARS-CoV-2 infection was 0{\textperiodcentered}57\% (n=2484) during days 1-12 and 0{\textperiodcentered}27\% (n=614) in days 13-24. A 51{\textperiodcentered}4\% relative risk reduction (RRR) was calculated in weighted-average daily incidence of SARS-CoV-2 infection from 43{\textperiodcentered}41-per-100,000(SE=12{\textperiodcentered}07) in days 1-12 to 21{\textperiodcentered}08-per-100,000(SE=6{\textperiodcentered}16) in days 13-24 following immunization. The decrement in incidence was evident from day 18 after first dose. Similar RRRs were calculated in individuals aged 60 or above (44.5\%), younger individuals (50.2\%), females (50.0\%) and males (52.1\%). Findings were similar in sub-populations and patients with various comorbidities.Conclusions We demonstrated an effectiveness of 51\% of BNT162b2 vaccine against SARS-CoV-2 infection 13-24 days after immunization with the first dose. Immunization with the second dose should be continued to attain the anticipated protection.Evidence before this study We searched PubMed for follow-up studies regarding the effectiveness of BNT162b2 mRNA Covid-19 Vaccine without any language restrictions. The search terms were (BNT162b2 OR mRNA Covid-19 Vaccine) AND (effectiveness OR real-world OR phase IV) until Jan 15, 2021. We found no relevant observational studies among humans. We also assessed Phase II and Phase III clinical trials with BNT162b2 mRNA vaccine.Added value of this study To our knowledge, this is the first and largest phase IV study on the effectiveness of the BNT162b2 mRNA COVID-19 vaccine in real-world settings. Our findings showed that the first dose of the vaccine is associated with an approximately 51\% reduction in the incidence of PCR-confirmed SARS-CoV-2 infections at 13 to 24 days after immunization compared to the rate during the first 12 days. Similar levels of effectiveness were found across age groups, sex, as well as among individuals residing in Arab or ultra-orthodox Jewish communities that display an increased COVID-19 risk.Implications of all the available evidence The study results indicate that in real life the first dose of the new BNT162b2 mRNA COVID-19 vaccine confers around 50\% protection against overall SARS-CoV-2 infections (symptomatic or asymptomatic). Together our findings and the 95\% efficacy shown in the phase III trial, suggest that the BNT162b2 vaccine should be administered in two doses to achieve maximum protection and impact in terms of disease burden reduction and possibly reducing SARS-CoV-2 transmission. COVID-19 vaccines should be urgently deployed globally.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Maccabi Healthcare Services IRBAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData cannot be shared due to regulatory limitations}, URL = {https://www.medrxiv.org/content/early/2021/01/29/2021.01.27.21250612}, eprint = {https://www.medrxiv.org/content/early/2021/01/29/2021.01.27.21250612.full.pdf}, journal = {medRxiv} }